Pain Sensitivity and Pruritus of Peripheral Nerves
Pain Sensitivity and Pruritus of Peripheral Nerves - Can we Differentiate These Signals by Use of Pharmacological Modulation and Human Experimental Research?
Previous research has demonstrated that itch and pain share several underlying neural pathways and signaling molecules. Understanding these common mechanisms is important for developing more effective therapeutic strategies targeting both sensations. Mepyramine, an antihistamine, has been reported to exert effects on both itch and pain perception. This study aims to investigate these effects using established experimental models of itch and pain. Itch will be induced using histamine, a naturally occurring substance in the human body, and spicules from the plant Mucuna pruriens (cowhage), while electrical stimulation will be used to assess pain-related responses. By combining these experimentais approaches, the project aims to better understand how mepyramine influences different sensory mechanisms. The overall purpose of this study is to evaluate the effects of mepyramine on experimentally induced itch and pain in healthy volunteers.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Aalborg
-
Gistrup, Aalborg, Denmark, 9260
- Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University Selma Lagerløfs Vej 249 9260 Gistrup, Denmark
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy men and women aged 18-60 years
- Speak and understand English
Exclusion Criteria:
-
Pregnancy or lactation
-
Drug addiction defined as any use of cannabis, opioids, or other drugs that may cause addiction.
-
History of peripheral or chronic pain conditions, neuropathy, neurological, dermatological, or psychiatric diagnoses that may affect the results.
- Moles, wounds, scars, or tattoos in the area to be treated or tested
- Current use of medications that may affect the trial such as antihistamines, painkillers, antidepressants, or anticonvulsants
- Use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment.
- Application of moisturizing lotion of the volar site of the forearms (24 hours before study start)
- Previous traumatic experience of an electrical accident
- Participation in any other research projects/studies 7 days before study start
- Known allergy/intolerance to mepyramine
- The subject is assessed as unable to engage in the necessary cooperation required by the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventions
This subproject will be conducted in one single session lasting approximately 4-5 hours. In each forearm of the participant, two 4x4 cm areas will be selected as Area of Interest (AOI). In these selected areas, the same cream will be applied for 1 hour. After the cream removal, itch will be induced using histamine and cowhage (the order of histamine and cowhage will be randomized). During the application of the substances, the itch/pain elicited will be monitored for 10 minutes using a VAS (Visual analog scale). After the removal of the substances, measurements of SBP, MEI, PTT MPT, MPS, and thermal sensitivity will be conducted. |
About 30 spicules will be applied on the selected areas and inserted manually Mepyramine cream 2% One drop of histamine will be applied on the selected areas and pierced with a lancet. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measuring itch by computerized Visual Analog Scale Scoring
Time Frame: During Histamine/cowhage application
|
We will ask the subjects to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates |
During Histamine/cowhage application
|
|
Superficial blood perfusion
Time Frame: Before pruritogen application
|
Before pruritogen application
|
|
|
Superficial blood perfusion
Time Frame: 1 minute after pruritogen removal
|
1 minute after pruritogen removal
|
|
|
Superficial blood perfusion
Time Frame: 1 minute after cream+pruritogen removal
|
1 minute after cream+pruritogen removal
|
|
|
Perception threshold tracking model (PTT)
Time Frame: Before cream application
|
Before cream application
|
|
|
Perception threshold tracking model (PTT)
Time Frame: 1 minute after cream removal
|
1 minute after cream removal
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mechanically evoked itch (MEI)
Time Frame: 2 minute after pruritogen removal
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
2 minute after pruritogen removal
|
|
Mechanically evoked itch (MEI)
Time Frame: 2 minute after cream+pruritogen removal
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
2 minute after cream+pruritogen removal
|
|
Mechanical Pain Thresholds (MPT)
Time Frame: 5 minute after pruritogen removal
|
This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
5 minute after pruritogen removal
|
|
Mechanical Pain Thresholds (MPT)
Time Frame: 5 minute after cream+pruritogen removal
|
This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
5 minute after cream+pruritogen removal
|
|
Mechanical Pain Sensitivity (MPS)
Time Frame: 8 minute after pruritogen removal
|
This test is conducted with the same pinprick set used to test the MPT. |
8 minute after pruritogen removal
|
|
Mechanical Pain Sensitivity (MPS)
Time Frame: 8 minute after cream+pruritogen removal
|
This test is conducted with the same pinprick set used to test the MPT. |
8 minute after cream+pruritogen removal
|
|
Cold Detection Thresholds (CDT)
Time Frame: 10 minute after pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after pruritogen removal
|
|
Cold Detection Thresholds (CDT)
Time Frame: 10 minute after cream+pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after cream+pruritogen removal
|
|
Warm Detection Thresholds (WDT)
Time Frame: 10 minute after pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after pruritogen removal
|
|
Warm Detection Thresholds (WDT)
Time Frame: 10 minute after cream+pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after cream+pruritogen removal
|
|
Cold Pain Thresholds (CPT)
Time Frame: 10 minute after pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after pruritogen removal
|
|
Cold Pain Thresholds (CPT)
Time Frame: 10 minute after cream+pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after cream+pruritogen removal
|
|
Heat Pain Thresholds (HPT)
Time Frame: 10 minute after pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after pruritogen removal
|
|
Heat Pain Thresholds (HPT)
Time Frame: 10 minute after cream+pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after cream+pruritogen removal
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Time Frame: 10 minute after pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after pruritogen removal
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Time Frame: 10 minute after cream+pruritogen removal
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
10 minute after cream+pruritogen removal
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- N-20260019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.